June 12, 2017 / 9:14 PM / 2 years ago

First bellwether over AbbVie's AndroGel ends in mistrial

A mistrial was declared on Monday in the first case to go to trial out of thousands of lawsuits claiming AbbVie Inc failed to warn of the risk that its testosterone-replacement therapy AndroGel could cause heart attacks, strokes and other injuries.

A week after trial began in the case, U.S. District Judge Matthew Kennelly in Chicago declared the mistrial due to one of the lawyers developing an illness, according to a court official.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2rTFhDn

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below